Source and scope
This summary is bounded to the recommendations, population and decisions covered by Diagnosis and management of patients with polyneuropathy. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CMAJ polyneuropathy
Source-attributed clinical priorities
- Define the tempo and distribution, confirm objective sensory or motor findings and identify urgent asymmetric or rapidly progressive patterns.
- Investigate common treatable causes through history, examination and targeted laboratory testing rather than broad untargeted panels.
- Treat the cause where possible, protect insensate feet and use neuropathic-pain treatment only when painful symptoms warrant it.
- Tempo and pattern determine urgency: a chronic symmetric sensory neuropathy differs from an acute multifocal motor process.
sources for this section:CMAJ polyneuropathy
Practical assessment and management workflow
1
Document sensory, motor, autonomic and pain symptoms and exposure to diabetes, alcohol, chemotherapy and nutritional risk.
2
Examine reflexes, strength, gait, vibration, pin sensation and feet and identify asymmetry or a sensory level.
3
Order focused glucose, blood count, renal, liver, thyroid, B12 and paraprotein testing as clinically indicated.
4
Treat the cause, institute foot protection and arrange neurology or electrodiagnostic review for atypical disease.
sources for this section:CMAJ polyneuropathy
Safety, red flags and urgent escalation
- Ascending weakness, bulbar symptoms, respiratory difficulty or severe autonomic instability requires emergency assessment.
- Urgently investigate a rapidly progressive, asymmetric or predominantly motor neuropathy.
- Do not use neuropathic-pain medicine for numbness alone when it adds sedation without a symptomatic target.
sources for this section:CMAJ polyneuropathy
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CMAJ polyneuropathy
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CMAJ polyneuropathy
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Medical Association JournalDiagnosis and management of patients with polyneuropathyCMAJ 2023;195:E227-E233; DOI 10.1503/cmaj.220936 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.